These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38830017)

  • 21. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 22. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical safety of remdesivir therapy in COVID-19 patients with renal insufficiency.
    Park S; Kim AR; Lee J; Kang SW; Sung H; Kim MN; Chang E; Bae S; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Song EH; Chong YP
    J Infect Chemother; 2024 Apr; 30(4):366-370. PubMed ID: 37935348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.
    Schreiber A; Bauzon JS; Batra K; Mohammed S; Lee K; Houshmand N; Pham U; Cosme C; Inciong K; Al-Taweel O; Nasser K; Rana J; Sossou C; Go A; Hawwass D; Diep J; Ahsan CH
    Clin Drug Investig; 2022 Sep; 42(9):763-774. PubMed ID: 35978159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Ackley TW; McManus D; Topal JE; Cicali B; Shah S
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compassionate Use of Remdesivir in Children With Severe COVID-19.
    Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
    Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
    Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.
    Attena E; Albani S; Maraolo AE; Mollica M; De Rosa A; Pisapia R; Fiorentino G; Parrella R; Severino S; Russo V
    Circ Arrhythm Electrophysiol; 2021 Jul; 14(7):e009811. PubMed ID: 34182791
    [No Abstract]   [Full Text] [Related]  

  • 32. Compassionate Use of Remdesivir for Patients with Severe Covid-19.
    Grein J; Ohmagari N; Shin D; Diaz G; Asperges E; Castagna A; Feldt T; Green G; Green ML; Lescure FX; Nicastri E; Oda R; Yo K; Quiros-Roldan E; Studemeister A; Redinski J; Ahmed S; Bernett J; Chelliah D; Chen D; Chihara S; Cohen SH; Cunningham J; D'Arminio Monforte A; Ismail S; Kato H; Lapadula G; L'Her E; Maeno T; Majumder S; Massari M; Mora-Rillo M; Mutoh Y; Nguyen D; Verweij E; Zoufaly A; Osinusi AO; DeZure A; Zhao Y; Zhong L; Chokkalingam A; Elboudwarej E; Telep L; Timbs L; Henne I; Sellers S; Cao H; Tan SK; Winterbourne L; Desai P; Mera R; Gaggar A; Myers RP; Brainard DM; Childs R; Flanigan T
    N Engl J Med; 2020 Jun; 382(24):2327-2336. PubMed ID: 32275812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study.
    Abedipour F; Mirzaei HH; Ansari H; Ehsanzadeh N; Rashki A; Vahedi MM; Rashki A
    Drug Res (Stuttg); 2024 Jul; 74(6):290-295. PubMed ID: 38968952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
    Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
    Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.
    Mehta RM; Bansal S; Bysani S; Kalpakam H
    Int J Infect Dis; 2021 May; 106():71-77. PubMed ID: 33647517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
    Wilt TJ; Kaka AS; MacDonald R; Greer N; Obley A; Duan-Porter W
    Ann Intern Med; 2021 Feb; 174(2):209-220. PubMed ID: 33017170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
    Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
    Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City.
    Mgbako O; Mehta M; Dietz D; Neidell MJ; Huang SE; Zucker J; Shoucri S; Kubin CJ; Castor D
    Ethn Dis; 2023 Jan; 33(1):1-8. PubMed ID: 38846265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
    Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
    CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.